Profile data is unavailable for this security.
About the company
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicine and Chemical Medicine segment is engaged in the manufacture, sale and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is principally engaged in the long term and short term investments. The Other segment is principally engaged in the related medical and hospital business.
- Revenue in HKD (TTM)29.49bn
- Net income in HKD2.20bn
- Incorporated2000
- Employees24.44k
- LocationSino Biopharmaceutical LtdUnit 09, 41F, Office TowerConvention Plaza, No. 1 Harbour RoadWanchai Hong KongHKG
- Phone+852 28029886
- Fax+852 28800847
- Websitehttp://www.sinobiopharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
China Resources Pharmaceutical Group Ltd | 275.73bn | 4.15bn | 31.16bn | 72.76k | 7.50 | 0.5855 | 2.45 | 0.113 | 0.6613 | 0.6613 | 43.89 | 8.47 | 0.966 | 6.09 | 3.00 | 3,777,819.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
CSPC Pharmaceutical Group Ltd | 26.80bn | 4.97bn | 55.62bn | 20.30k | 11.18 | 1.45 | 14.05 | 2.08 | 0.4196 | 0.4196 | 2.25 | 3.22 | 0.5319 | 2.30 | 4.03 | 1,140,410.00 | 10.14 | 16.08 | 13.50 | 21.57 | 71.59 | 72.95 | 19.07 | 19.63 | 2.22 | 111.64 | 0.0106 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
Sino Biopharmaceutical Ltd | 29.49bn | 2.20bn | 62.01bn | 24.44k | 27.66 | 1.67 | 9.74 | 2.10 | 0.1193 | 0.2442 | 1.60 | 1.97 | 0.4050 | 2.37 | 3.74 | 1,142,743.00 | 7.42 | 13.11 | 14.50 | 21.74 | 82.92 | 80.37 | 18.33 | 27.47 | 1.07 | 11.10 | 0.1868 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
Innovent Biologics Inc | 8.21bn | -1.41bn | 68.75bn | 5.26k | -- | 5.02 | -- | 8.38 | -0.8837 | -0.8837 | 5.12 | 8.40 | 0.3905 | 1.32 | 6.25 | 1,684,355.00 | -6.71 | -13.06 | -8.22 | -15.85 | 82.44 | 84.51 | -17.18 | -43.44 | 2.51 | -3.68 | 0.2123 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
Data as of Sep 20 2024. Currency figures normalised to Sino Biopharmaceutical Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 04 Sep 2024 | 364.92m | 1.94% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 182.99m | 0.97% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 182.97m | 0.97% |
Aegon-Industrial Fund Management Co., Ltd.as of 31 Dec 2023 | 182.75m | 0.97% |
Hang Seng Investment Management Ltd.as of 05 Sep 2024 | 175.33m | 0.93% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 140.62m | 0.75% |
Norges Bank Investment Managementas of 31 Dec 2023 | 130.33m | 0.69% |
Dimensional Fund Advisors LPas of 05 Sep 2024 | 115.08m | 0.61% |
BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 114.75m | 0.61% |
China Asset Management Co., Ltd.as of 31 Dec 2023 | 77.66m | 0.41% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.